Academic Journal
Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses.
| Title: | Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses. |
|---|---|
| Authors: | Zhang M; Pharmacy Department, The First Hospital of Hebei Medical University, Hebei Shijiazhuang, 050000, China., Zhang F; Pharmacy Department, The First Hospital of Hebei Medical University, Hebei Shijiazhuang, 050000, China., Tian C; Pharmacy Department, The First Hospital of Hebei Medical University, Hebei Shijiazhuang, 050000, China., Zhang Y; Graduate School of Hebei Medical University, Hebei Shijiazhuang, 050011, China., Wang C; Pharmacy Department, The First Hospital of Hebei Medical University, Hebei Shijiazhuang, 050000, China., Zhang H; Pharmacy Department, The First Hospital of Hebei Medical University, Hebei Shijiazhuang, 050000, China. 18240359116@163.com., Zhang L; Pharmacy Department, The First Hospital of Hebei Medical University, Hebei Shijiazhuang, 050000, China. jason752564@sina.com. |
| Source: | Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2026 Sep; Vol. 60 (5), pp. 1440-1452. Date of Electronic Publication: 2026 May 28. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101597411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2168-4804 (Electronic) Linking ISSN: 21684790 NLM ISO Abbreviation: Ther Innov Regul Sci Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2020- : Cham, Switzerland : Springer International Publishing Original Publication: Thousand Oaks, CA : Sage Publications, [2013]- |
| MeSH Terms: | Palonosetron*/economics , Palonosetron*/therapeutic use , Vomiting*/chemically induced , Vomiting*/prevention & control , Vomiting*/drug therapy , Vomiting*/economics , Antineoplastic Agents*/adverse effects , Nausea*/chemically induced , Nausea*/prevention & control , Nausea*/drug therapy , Nausea*/economics , Antiemetics*/economics , Antiemetics*/therapeutic use , Pyridines*/economics , Pyridines*/therapeutic use, Humans ; Cost-Benefit Analysis ; Economics, Pharmaceutical ; Cost-Effectiveness Analysis ; Piperazines ; Benzeneacetamides |
| Abstract: | Introduction: This study was conducted to systematically evaluate the economic profile of netupitant palonosetron(NEPA) for the prevention of chemotherapy-induced nausea and vomiting(CINV)in patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). The goal is to provide evidence-based support for optimizing clinical medication decisions and standardizing future pharmacoeconomic research. Methods: Literature was searched through different Chinese and English databases from database inception to March 16, 2025, with study quality assessed using the CHEERS checklist. Most evaluations utilized cost-utility analysis via Markov or decision tree models, primarily focusing on direct medical costs from healthcare payer or system perspectives. Results: Nine studies meeting the inclusion criteria were analyzed. The results confirm the economic advantages of NEPA for CINV prophylaxis. In Western healthcare systems (UK, Spain, Italy, and the US), NEPA was frequently identified as a dominant strategy, providing greater health benefits (QALYs) at lower total costs. In China, NEPA was shown to be cost-effective at a willingness-to-pay (WTP) threshold equivalent to one times the national GDP per capita. Sensitivity analyses revealed that the cost-effectiveness of NEPA is highly sensitive to local drug pricing and variations in clinical practice. Conclusion: NEPA is a cost-effective or even dominant strategy for CINV prophylaxis in both HEC and MEC populations. These findings provide a scientific basis for drug reimbursement negotiations and clinical pathway optimization. Future research should utilize real-world evidence across multiple chemotherapy cycles to further validate its long-term economic value and support value-based healthcare decisions. (© 2026. The Author(s), under exclusive licence to The Drug Information Association, Inc.) |
| Competing Interests: | Declarations. Conflict of interest: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. |
| References: | Dranitsaris G, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260–7. (PMID: 10.1093/annonc/mdx100283985305452068) Lorusso D et al. Patients’ perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care (Engl), 2017. 26(2). Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26:100278. (PMID: 33360668) Aapro M, et al. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken). 2018;1(4):e1127. (PMID: 327292527941545) Heckroth M, et al. Nausea and vomiting in 2021: a comprehensive update. J Clin Gastroenterol. 2021;55(4):279–99. (PMID: 10.1097/MCG.0000000000001485334714857933092) Oncology CSoC. Chinese society of cancer supportive care. Chinese expert consensus on the prevention and treatment of nausea and vomiting associated with antineoplastic drugs (2022 edition). Natl Med J China. 2022;102(39):3080–94. NCCN. National comprehensive cancer network. clinical practice guidelines in oncology: antiemesis. v. 1.2022; 2022. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73(3):249–62. (PMID: 10.1007/s40265-013-0019-123404093) Yunpeng Y. Netupitant and palonosetron hydrochloride capsules, a new fixed-dose combination drug for the prevention of chemotherapy-induced nausea and vomiting. Chin Clin Oncol. 2021;26(8):750–5. Hesketh PJ, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–97. (PMID: 10.1200/JCO.20.0129632658626) Roila F et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol, 2016. 27(suppl 5):119–133. Zhang, Bin. L.I.X.-l., Adherence to clinical guidelines for prophylaxis of chemotherapy induced nausea and vomiting. Chin J Hosp Pharm. 2018;38(12):1325–9. Zhang L, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452–8. (PMID: 10.1093/annonc/mdx698290920125834144) Chang J, et al. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med. 2020;9(14):5134–42. (PMID: 10.1002/cam4.3123324727427367622) Husereau D, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Health Policy Open. 2022;3:100063. (PMID: 10.1016/j.hpopen.2021.1000633738357010297740) Consolidated health economic evaluation reporting standards (CHEERS) 2022 Explanation and elaboration: a report of the ISPOR CHEERS Ii good practices task force. Value Health, 2022. 25(6):1060. Ran Q, et al. A systematic review of the cost-effectiveness of therapeutic drugs for anaplastic lymphoma kinase-positive non-small cell lung cance. China Pharm. 2022;33(11):1368–73. Liangliang D, Kun L, Xiuhua W. Cost-utility analysis of drugs for prevention and treatment of chemotherapy-induced nausea and vomiting. Chin J Mod Appl Pharm. 2022;39(17):2257–61. Li-Li C, et al. Cost-effectiveness of netupitant-palonosetron capsule in the treatment of chemotherapy-induced nausea and vomiting. Chin J Pharmacoeconomics. 2023;18(7):11–6. Yu Z, et al. Pharmacoeconomic evaluation of netupitant/palonosetron for preventing carboplatin-induced nausea and vomiting under diagnosis-related groups payment system. Chin J Hosp Pharm. 2024;44(8):956–60. Botteman M, et al. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer. 2020;28(2):857–66. (PMID: 10.1007/s00520-019-04824-y31161436) Cawston H, et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017;6:212298. (PMID: 10.7573/dic.212298283928265378057) Nilsson J, et al. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer. 2022;30(11):9307–15. (PMID: 10.1007/s00520-022-07339-1360741869633536) Restelli U, et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open. 2017;7(7):e015645. (PMID: 10.1136/bmjopen-2016-015645287651265642784) Giuliani J, Bonetti A. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment. Expert Rev PharmacoEcon Outcomes Res. 2019;19(5):505–8. (PMID: 10.1080/14737167.2019.165064431379219) Nelson WW, et al. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy. Future Oncol. 2023;19(1):29–36. (PMID: 10.2217/fon-2022-097236622264) Annemans L, et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer. 2008;16(8):905–15. (PMID: 10.1007/s00520-007-0349-117965891) Lordick F, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007;43(2):299–307. (PMID: 10.1016/j.ejca.2006.09.01917134890) Börjeson S, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs. 1997;20(4):260–6. (PMID: 10.1097/00002820-199708000-000059265812) Grunberg SM, et al. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 1996;4(6):435–9. (PMID: 10.1007/BF018806418961474) Hesketh PJ, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340–6. (PMID: 10.1093/annonc/mdu110246081964071755) Aapro M, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328–33. (PMID: 10.1093/annonc/mdu101246036434071754) Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112(9):2080–7. (PMID: 10.1002/cncr.2336418327813) Yaozhi D. 2021 [2021-11-2]. Chanthawong S, et al. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer. 2019;27(3):1109–19. (PMID: 10.1007/s00520-018-4400-130112718) Sun CC, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118–28. (PMID: 10.1006/gyno.2002.680712468352) Schmoll HJ, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17(6):1000–6. (PMID: 10.1093/annonc/mdl01916524979) Q1 CMS Payment Lions and 2018 CMS Medicare Fee Schedule (2018) retrieved from CMS, centers for medicare & medicaid services. 2018; Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/. PBMI drug benefit report (2015). 2018; Available from: https://www.pbmi.com/ItemDetail?iProductCode=2014-2015_BDRCategory=BDRWebsiteKey=0a635f1b-bb59-4687-8a69-2a4c2892992b. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131–40. (PMID: 10.1007/s00520-009-0797-x20101417) Benson AB et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2024;22(2d). Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189–98. (PMID: 10.1200/JCO.2010.34.4614219478344876353) Humphreys S, Pellissier J, Jones A. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res. 2013;5:215–24. (PMID: 10.2147/CMAR.S44539239506583742066) Abdel-Rahman O. Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. Ther Adv Med Oncol. 2016;8(5):396–406. (PMID: 10.1177/1758834016654902275830324981292) Ihbe-Heffinger A, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15(3):526–36. (PMID: 10.1093/annonc/mdh11014998860) Gralla RJ, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7):1333–9. (PMID: 10.1093/annonc/mdu096246319494071753) Shimizu H, et al. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). J Pharm Health Care Sci. 2018;4:31. (PMID: 10.1186/s40780-018-0128-9305557106287343) Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678–85. (PMID: 10.1002/cncr.2282317567835) |
| Grant Information: | 20250369 Hebei Provincial Medical Science Research Project Plan; JYB240310 Hebei Provincial Healthcare Security Research Project |
| Contributed Indexing: | Keywords: Chemotherapy-induced nausea and vomiting; Netupitant palonosetron; Pharmacoeconomic; Systematic analysis |
| Substance Nomenclature: | 5D06587D6R (Palonosetron) 0 (Antineoplastic Agents) 0 (Antiemetics) 0 (Pyridines) 7732P08TIR (netupitant) 0 (Piperazines) 0 (Benzeneacetamides) |
| Entry Date(s): | Date Created: 20260528 Date Completed: 20260829 Latest Revision: 20260829 |
| Update Code: | 20260830 |
| DOI: | 10.1007/s43441-026-00979-z |
| PMID: | 42207482 |
| Database: | MEDLINE |
| ISSN: | 2168-4804 |
|---|---|
| DOI: | 10.1007/s43441-026-00979-z |